Allarity Therapeutics Aktie

Allarity is proceeding as planned with a GMP‑compliant manufacturing campaign for the active substance Stenoparib, which is to be completed no later than Q3 2026. Production is taking place at a European CDMO according to FDA and EMA standards; all manufacturing‑related payments have been made and no further cash outlays are expected. Stenoparib is intended to support clinical development in an approval‑relevant study for advanced ovarian cancer; the compound has FDA Fast‑Track status and is also in several phase‑2 studies. » Plus sur de.investing.com

The US Patent and Trademark Office has issued a Notice of Allowance for Allarity Therapeutics' DRP companion diagnostic for stenoparib; the formal patent grant is expected within three months. The patent would secure exclusivity until at least 2039 and covers methods for predicting clinical benefit and selecting patients based on gene expression profiles. The stock rose 7.2% over the week; Allarity is currently conducting several Phase II studies with stenoparib and already holds granted patents in Europe and Australia, while applications in other countries are pending. » Plus sur de.investing.com

Allarity presented two posters at the AACR meeting: a phase‑2 analysis shows that higher values of the company’s Drug Response Predictor correlate with improved overall survival in women with advanced, recurrent ovarian cancer treated with Stenoparib. A second poster demonstrates that Stenoparib inhibits the WNT signaling pathway and blocks the growth of human colorectal cancer cell lines at clinically relevant concentrations. The company has a market capitalization of around 19.77 million USD, more cash than debt and a current ratio of 2.13, is running several phase‑2 programs, and analysts cite a price target of 9.75 USD. » Plus sur de.investing.com